Clinical trials: Heart Failure (HF)
Heart Failure
A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function
The purpose of this study is to determine the minimum effective dose of Istaroxime, in patients requiring hospitalization for deterioration of chronic heart failure and left ventricular systolic dysfunction.
- Trial name
- HORIZON-HF (NCT00616161)
- Testing
- Istaroxime
- Volunteers
- 120 people
- Sponsor
- sigma-tau i.f.r. S.p.A.
Heart Failure, Congestive
X-Change HF - Exchange of the Existing Pacemaker/ICD in Bradycardia Patients Suffering From Heart Failure
The goal of X-Change HF is to estimate the effect of biventricular stimulation in patients who need antibradycardia ventricular stimulation (more than 80%); are eligible for the exchange of an old pacemaker or implantable…
- Trial name
- NCT00157846
- Testing
- CRT-P or CRT-D Device
- Where
- 10 sites in Germany
- Volunteers
- 36 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
OptiLink HF Study: Optimization of Heart Failure Management Using Medtronic OptiVol Fluid Status Monitoring and CareLink Network
Patients suffering from heart failure and a markedly reduced pumping capacity and sometimes desynchronization of the lower chambers of the heart have a higher risk of suffering sudden cardiac death.
- Trial name
- OptiLink-HF (NCT00769457)
- Testing
- Access Arm
- Where
- Germany
- Volunteers
- 1,002 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure
A Crossover Study of Patients With HF to Compare Natriuretic Effects of IR Torsemide vs. ER Torsemide Over 12 Hrs
This is a randomized double-blind crossover study of the patients with stable heart failure, who are taking a loop diuretic. During the study period, the participants' loop diuretics will be replaced by the equivalent dose of…
- Trial name
- EXTOR-HF (NCT06708611)
- Testing
- torsemide
- Where
- United States
- Sponsor
- Sarfez Pharmaceuticals, Inc.
Heart Failure, Systolic Heart Failure
Heart Failure (HF) Outpatient Monitoring Evaluation (HOME) Study
The purpose of this study is to determine if heart failure subjects whose treatment is assisted by home BNP measurements integrated into a home health management system will have better clinical outcomes than subjects whose…
- Conditions
- Heart Failure, Systolic Heart Failure, Acute Decompensated Heart Failure
- Trial name
- HOME (NCT01347567)
- Testing
- Interventions with heart failure medications
- Where
- 7 sites in Australia, Ireland and 4 more
- Volunteers
- 145 people
- Sponsor
- Alere San Diego
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Cardiomyopathy
An Open Label Rollover Trial for Patients Randomized to the Control Group of Study LSH-10-001
The objective of this extension study is to evaluate the safety and potential beneficial effects of the Algisyl-LVR™ device in patients with established heart failure secondary to a dilated cardiomyopathy.
- Conditions
- Heart Failure, Cardiomyopathy, Dilated Cardiomyopathy
- Trial name
- NCT02226679
- Testing
- Algisyl-LVR
- Where
- 2 sites in Italy, Romania
- Volunteers
- 24 people
- Sponsor
- LoneStar Heart, Inc.
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Heart Failure, Arrhythmia
BIO|CONCEPT.BIOMONITOR-HF Collect Clinical Data From Heart Failure Patients Using BIOMONITOR Devices With a Study Specific Research Software
[Plain language]: Heart failure (HF) patients often experience irregular heartbeats, known as arrhythmias. Atrial fibrillation (AF) is common among HF patients and can worsen their condition, leading to strokes and higher death…
- Conditions
- Heart Failure, Arrhythmia, Decompensated Heart Failure, Atrial Fibrillation
- Trial name
- NCT06989580
- Testing
- BIOMONITOR IV with study software
- Where
- 2 sites in Belgium, Germany
- Volunteers
- 300 people
- Sponsor
- Biotronik SE & Co. KG
Heart Failure
Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)
Evaluation of the risk factors associated with Heart Failure (HF) worsening (measured by hospitalizations and emergency visits because of HF exacerbations) in Spanish patients with Atrial Fibrilation and HF treated with…
- Trial name
- FARAONIC (NCT03455439)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Spain
- Volunteers
- 552 people
- Sponsor
- Bayer
Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure
The purpose of this study is to evaluate the effect of dapagliflozin on the incidence of worsening heart failure or cardiovascular death in patients with chronic heart failure with reduced ejection fraction
- Trial name
- DAPA-HF (NCT03036124)
- Testing
- Dapagliflozin
- Where
- 419 sites in United States, Argentina and 18 more
- Volunteers
- 4,744 people
- Sponsor
- AstraZeneca
Atrial Fibrillation, Heart Failure
Post Market Clinical Follow-up of CRT-DX Therapy With Lumax 640/740 HF-T
The study is designed to collect data of the performance and confirm the safety of the DX (Diagnostic eXtension) functionality in the Lumax 640/470 HF-T in patients with permanent atrial fibrillation and CRT-D indication…
- Trial name
- Pre-CRAFT (NCT01930695)
- Where
- 5 sites in Germany, Switzerland
- Volunteers
- 18 people
- Sponsor
- Biotronik SE & Co. KG
Heart Failure
CardioMEMS HF System Coverage With Evidence Development Study
The purpose of the CardioMEMS CED Study is to determine if pulmonary artery (PA) pressure-guided heart failure management using the CardioMEMS™ HF System improves long-term health outcomes in heart failure (HF) patients in the…
- Trial name
- NCT06779552
- Testing
- CardioMEMS HF System
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Abbott Medical Devices
Heart Failure
HF Assessment With BNP in the Home: Part II
HABIT-II is a feasibility study aimed at home monitoring of patients with heart failure. B-type natriuretic peptide (BNP) has strong correlations to the severity of heart failure.
- Trial name
- HABIT-II (NCT02351063)
- Testing
- Changes of heart failure medications
- Where
- 13 sites in United States, Ireland and 4 more
- Volunteers
- 1 people
- Sponsor
- Alere San Diego
Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction
Study of JK07 in Patients With Chronic Heart Failure
This is a Phase 2, randomized, double-blind, placebo-controlled, multiple dose study to assess the safety, tolerability, and efficacy of JK07 in participants aged 18-85 with heart failure.
- Trial name
- RENEU-HF (NCT06369298)
- Testing
- JK07
- Where
- 62 sites in United States, Canada and 2 more
- Volunteers
- 282 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure, Congestive
HEAL-HF: A Cardiac Resynchronization Therapy (CRT) Outcomes Study
The literature shows that approximately 40% of individuals who receive a cardiac resynchronization therapy (CRT) device for symptomatic congestive heart failure (CHF) do not have a clinical benefit from the device.
- Trial name
- NCT00370526
- Testing
- Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement
- Where
- 5 sites in United States, Canada and 1 more
- Volunteers
- 100 people
- Sponsor
- Stereotaxis
Heart Failure
Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction
The purpose of this study is to determine if treatment with omecamtiv mecarbil when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in…
- Trial name
- GALACTIC-HF (NCT02929329)
- Testing
- Omecamtiv Mecarbil, Standard of Care
- Where
- 1,033 sites in United States, Argentina and 34 more
- Volunteers
- 8,256 people
- Sponsor
- Cytokinetics
Heart Failure
Acorai Machine Learning Generalization (MLG) Study
Acorai is developing a non-invasive monitoring system for the estimation of intracardiac hemodynamic parameters in patients with suspected or confirmed heart failure, and/or pulmonary hypertension, who require hemodynamic…
- Trial name
- CAPTURE-HF (NCT05835024)
- Testing
- Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 1, Acorai Sensor Data Collection (ASDC) system 1.0 - Phase 2
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 1,602 people, healthy volunteers welcome
- Sponsor
- Acorai AB
Heart Failure
Prospective Evaluation of Elastic Restraint to LESSen the Effects of Heart Failure (PEERLESS-HF) Trial
The purpose of this study is to determine if patients in the HeartNet Ventricular Support System with optimal medical and device therapy arm (Treatment group) show statistically significant improvement compared to patients in the…
- Trial name
- PEERLESS-HF (NCT00382863)
- Testing
- HeartNet Ventricular Support System, Optimal Medical/Device Therapy
- Where
- 35 sites in United States, Canada
- Volunteers
- 220 people
- Sponsor
- Paracor Medical, Inc
Chronic Heart Failure With Reduced Ejection Fraction
Omecamtiv Mecarbil Post-trial Access Study
The primary objective of this study is to provide access to omecamtiv mecarbil for participants who have completed GALACTIC-HF 20110203.
- Trial name
- NCT04464525
- Testing
- Omecamtiv mecarbil
- Sponsor
- Cytokinetics